University of Dundee School of Medicine

Pacylex Will Present Phase 1 Clinical Experience with PCLX-001 and Rationale for Expanding into Acute Myeloid Leukemia Patients at ASH 2022

Retrieved on: 
Thursday, November 3, 2022
NMT, Research, Non-Hodgkin lymphoma, AICE, Growth, Society, Lymphoma, University of Dundee School of Medicine, Safety, IND, Neoplasm, Wellcome Trust, ASH, University, Acute myeloid leukemia, Alberta Innovates, Defense, Family, Lung, NMT2, Cancer, Program, AML, Leukemia, Breast cancer, Patient, Survival, Pharmaceutical industry, Telescopic sight

The ongoing study is in Non-Hodgkin's Lymphoma and solid tumor patients and the company will present the non-clinical evidence that AML patients may benefit as well.

Key Points: 
  • The ongoing study is in Non-Hodgkin's Lymphoma and solid tumor patients and the company will present the non-clinical evidence that AML patients may benefit as well.
  • Pacylex non-clinical data which strongly supports expanding clinical investigations of PCLX-001 to acute myeloid leukemia (AML) will be presented at the American Society of Hematology Annual Meeting.
  • PCLX-001 safety experience in 17 lymphoma and solid tumor patients provides confidence to proceeding with a second clinical indication in AML.
  • Pacylex initiated clinical studies in Canada in the fall of 2021 in non-Hodgkin lymphoma and solid tumors and will soon initiate clinical studies in the US in acute myeloid leukemia patients.

Major Grant Awarded to Study PCLX-001 in Acute Myeloid Leukemia Patients

Retrieved on: 
Tuesday, October 11, 2022
Dasatinib, Lung, NMT, Leukemia, Alberta Innovates, Growth, Monroe Dunaway Anderson, NMT2, DOD, MD Anderson Cancer Center, Lymphoma, 5-MeO-NMT, Family, Neoplasm, Patient, Research, Program, Wellcome Trust, Cancer, University, Trial of the century, Acute myeloid leukemia, NHL, Breast cancer, Ibrutinib, Non-Hodgkin lymphoma, Survival, AICE, University of Dundee School of Medicine, Pharmaceutical industry, Telescopic sight, AML

PCLX-001 is being studied in non-Hodgkin lymphoma (NHL) and solid tumor cancer patients at 4 clinical sites in Canada.

Key Points: 
  • PCLX-001 is being studied in non-Hodgkin lymphoma (NHL) and solid tumor cancer patients at 4 clinical sites in Canada.
  • This investigation will be the first of an N-myristoyl transferase (NMT) inhibitor, PCLX-001, in AML patients.
  • This clinical study is the culmination of work done in AML (Acute Myeloid Leukemia) animal models for years combining insights on the role myristoylation may play in cancer with an NMT inhibitor Pacylex licensed for exclusive development.
  • This study in AML patients at MD Anderson will be the first clinical study of PCLX-001 in the US.

Nonacus Welcomes Two Senior Leadership Hires: Dr Andy Feber and Dr Samuel Clokie

Retrieved on: 
Wednesday, August 17, 2022
Genomics, Machine learning, Royal Marsden Hospital, Genetic testing, Precision medicine, University of Dundee School of Medicine, NIH, CEO, Division, Cancer Research UK, Diagnosis, Technology, Cancer, Research, Bioinformatics, Oncogenomics, Institute, Patient, DNA, Translation, Associate, Doctor of Philosophy, RNA-Seq, Artificial intelligence, Workflow, University, University College London, Liquid biopsy, Development, Dietary supplement, Medical imaging, Circadian rhythm, Biochemistry

BIRMINGHAM, England, Aug. 17, 2022 /PRNewswire/ -- Nonacus Ltd, leading provider of genetic testing products for precision medicine and liquid biopsy, is very pleased to announce the appointment of two senior leadership hires: Dr Andy Feber as Clinical Directorof Research and Development and Dr Samuel Clokie as Director of Bioinformatics & Data Science.

Key Points: 
  • BIRMINGHAM, England, Aug. 17, 2022 /PRNewswire/ -- Nonacus Ltd, leading provider of genetic testing products for precision medicine and liquid biopsy, is very pleased to announce the appointment of two senior leadership hires: Dr Andy Feber as Clinical Directorof Research and Development and Dr Samuel Clokie as Director of Bioinformatics & Data Science.
  • CEO of Nonacus, Chris Sale commented, "Our technology has now been proven in the liquid biopsy translational research and clinical setting.
  • Sam's responsibilities will encompass Bioinformatics team leadership and developing bioinformatic data analysis strategies to align with Nonacus' strategic objectives.
  • Nonacus provides a complete workflow for liquid biopsy analysis with the goal of enabling better cancer care through earlier diagnosis, treatment stratification and monitoring.

Amplity Health Appoints Nick Willhoft, Ph.D., as Head of Medical Communications

Retrieved on: 
Wednesday, February 2, 2022
Lynx, CEO, Culture, Patient, University, EVP, Physician, Database, Medical Communications for Combat Casualty Care, Doctor of Philosophy, Health, Syneos Health, University of Dundee School of Medicine, Precision medicine, GLOBE, Science, Head, Physiology, Solution, Pharmaceutical industry, Healthcare

LANGHORNE, Pa., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Amplity Health, a leading global medical and commercial partner to biopharmaceutical companies, today announced the expansion of its executive team with Nick Willhoft, Ph.D., as Head of Medical Communications.

Key Points: 
  • LANGHORNE, Pa., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Amplity Health, a leading global medical and commercial partner to biopharmaceutical companies, today announced the expansion of its executive team with Nick Willhoft, Ph.D., as Head of Medical Communications.
  • Willhoft's appointment follows Amplity's recent merger with The Lynx Group , whose capabilities formed Amplity Medical Communications.
  • Nick is a distinguished medical communications expert with years of experience framing scientific narratives and payer/patient value propositions."
  • Willhoft joins Amplity from CMC Affinity, where he was most recently Executive Vice President, U.S. Head of Medical Services.

Anupriya Grover-Wenk, DO is recognized by Continental Who's Who

Retrieved on: 
Monday, October 18, 2021
University of Dundee School of Medicine, American Family Physician, American Osteopathic Board of Family Physicians, Cambridge Health Alliance, Program, Family Practice (journal), Philadelphia College of Osteopathic Medicine, Scientist of the Year Award, Continental, Woman, AOBFP, Doctor of Pharmacy, Mentorship, Health, Tufts University, Osteopathic medicine in the United States, Imperial Society of Teachers of Dancing, Carnegie Mellon University, MS, Excepted service, York Hospital, American Board of Family Medicine, Tufts University School of Medicine, Patient, Curriculum, American Academy, Business administration, American Board of Commissioners for Foreign Missions, University, MD, DO, Medical education, Research, Female, Royal Devon and Exeter Hospital, Health insurance, Medicine

PORTSMOUTH, N.H., Oct. 18, 2021 /PRNewswire/ -- Anupriya Grover-Wenk, DO is being recognized by Continental Who's Who as a Trusted Family Medicine Specialist, and in recognition of her work at Appledore Family Medicine and Tufts University School of Medicine.

Key Points: 
  • PORTSMOUTH, N.H., Oct. 18, 2021 /PRNewswire/ -- Anupriya Grover-Wenk, DO is being recognized by Continental Who's Who as a Trusted Family Medicine Specialist, and in recognition of her work at Appledore Family Medicine and Tufts University School of Medicine.
  • She sees patients of all ages at Appledore Family Medicine, located at 7-C Mill Rd Plaza in Durham, NH.
  • As a Family Medicine Physician, she is often one of the first doctors her patients will see.
  • Dr. Grover-Wenk received her Bachelor of Science degree in Business Administration and Professional Writing from Carnegie Mellon University.